


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently Amended) A compound of Formula (I):



or a salt or solvate thereof,

wherein R¹ represents

a phenyl or naphthyl group, ~~[[()]]~~each of which is substituted by one or more substituents independently selected from -OH, -C₁₋₆alkyl, C₁₋₆haloalkyl, -OCH₂OCH₃, -C₁₋₆alkoxy, and -halogen,~~[[()]]~~ or

a mono or bicyclic heteroaryl group comprising 1, 2 or 3 nitrogen atoms, optionally substituted by -C₁₋₆alkoxy, -C₁₋₆alkyl, C₁₋₆haloalkyl or =O;

R² represents

H, benz[[o]]imidazolyl, benzothiazolyl, piperonyl, isoquinolinyl, ~~or~~ quinolinyl ~~group~~, or

phenyl wherein ~~[[()]]~~said phenyl ~~being~~ is optionally substituted by -NR³R⁴, -C₁₋₄alkoxy, -C₁₋₆alkyl, -CONR³R⁴, -SO₂NR³R⁴, -NHCONR³R⁴, -NHCOC₁₋₆alkyl, -C₁₋₆haloalkyl, ~~OCH₂O~~, phenoxy, NH₂ substituted ~~[[(-)]]~~phenoxy ~~(wherein the phenyl moiety is optionally substituted by NH₂), -C₁₋₃alkyl, -C₁₋~~

alkoxy, -CF₃, or -5 membered heteroaryl group comprising one or two nitrogen atoms[()];

R³ and R⁴ are independently selected from H, -C₁₋₆alkyl, -C₁₋₃alkylNR⁵R⁶; and

R⁵ and R⁶ are independently H or C₁₋₃alkyl[(:)];

~~or a salt, solvate, or physiologically functional derivative thereof.~~

2. (Currently Amended) A compound according to claim 1 wherein R¹ is
phenyl [(:)]substituted by one or more substituents selected from -OCH₂OCH₃, -OH, -halogen, -OCH₃[(:)],
OH substituted naphthyl (substituted by OH),
indoliny, quinoliny, or
a pyridiny moiety ~~(wherein the pyridiny moiety is optionally substituted by -OCH₃ or = O[(:)])~~.
3. (Original) A compound according to claim 2 wherein R¹ is phenyl substituted by OH.
4. (Currently Amended) A compound according to claim 3 wherein the OH is ~~on the 5 position of the phenyl ring~~ substituted meta to the depicted point of attachment of the phenyl to the isoquinoline.
5. (Currently Amended) A compound according to claim[(:)] 1 [(- 4)] wherein R² is
H, benz[(:)]imidazolyl, benzothiazolyl, piperonyl, quinoline, or
phenyl [(:)] wherein said phenyl is optionally substituted by -SO₂NH₂, CF₃, -CONH₂, -imidazolyl, -OCH₃, C₁₋₃ alkyl, ~~-OCH₂O-~~, CONHCH₂CH₂N(CH₂CH₃)₂, ~~-O-phenyl (where the phenyl is substituted by NH₂),~~ NH₂ substituted phenoxy, -NHCOCH₃, NH₂, or NHCOCH₃, ~~or benzoimidazolyl or benzothiazolyl moiety.~~

6. (Currently Amended) A compound according to claim 5 where in R^2 is a quinoline moiety, ~~a quinoline-6-yl moiety.~~

7. (Original) A compound according to claim 6 wherein R^2 is a quinoline 6-yl moiety.

8. (Currently Amended) A compound as claimed in claim 1, selected from the group consisting of:

5-(Indol-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
 5-(2-Methoxypyridin-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
 5-(Pyridin-2-on-5-yl)-1-(quinolin-6-yl)aminoisoquinoline;
 5-(4-Methoxymethoxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
 5-(4-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
 5-(3-Fluoro-4-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
 1-Amino-5-(indol-5-yl)isoquinoline;
 1-Amino-5-(2-methoxypyridin-5-yl)isoquinoline;
 1-Amino-5-(pyridin-2-on-5-yl)isoquinoline;
 1-Amino-5-(3-methoxyphenyl)isoquinoline;
 5-(2-Hydroxynaphthalen-6-yl)-1-(quinolin-6-yl)aminoisoquinoline;
 5-(4-Chloro-3-hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
 3-[5-(4-Chloro-3-hydroxyphenyl)-isoquinolin-1-

ylamino]benzenesulfonamide;

5-(3-Hydroxyphenyl)-1-(4-trifluoromethylphenyl)aminoisoquinoline;
 5-(3-Hydroxyphenyl)-1-(quinolin-6-yl)aminoisoquinoline;
 1-(4-Aminocarbonylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;
 5-(3-Hydroxyphenyl)-1-[4-(imidazol-1-yl)phenyl]aminoisoquinoline;
 3-[5-(3-Hydroxyphenyl)-isoquinolin-1-ylamino]benzenesulfonamide;
 5-(3-Hydroxyphenyl)-1-(3-methoxyphenyl)aminoisoquinoline;
 1-(3-Ethylphenyl)amino-5-(3-hydroxyphenyl)isoquinoline;
 N-(2-Diethylaminoethyl)-4-[5-(3-hydroxyphenyl)isoquinolin-1-

ylamino]benzamide;

1-(3-(4-Aminophenoxy)phenyl)amino-5-(3-hydroxyphenyl)isoquinoline;
5-(3-Hydroxyphenyl)-1-phenylaminoisoquinoline;
5-(3-Hydroxyphenyl)-1-(3,4-methylenedioxyphenyl)aminoisoquinoline;
1-Amino-5-(3-hydroxyphenyl)isoquinoline;
1-(Benzothiazol-6-yl)amino-5-(3-hydroxyphenyl)isoquinoline ;
1-(Benzimidazol-5-yl)amino-5-(3-hydroxyphenyl)isoquinoline ;
1-(3-Aminophenyl)amino-5-(3-hydroxyphenyl)isoquinoline ;
{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}urea ; and
N-{3-[5-(3-Hydroxyphenyl)isoquinolin-1-ylamino]phenyl}acetamide;

or a salt[[,]] or solvate, ~~or physiologically functional derivative~~ thereof.

9. (Currently Amended) A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim[[s]] 1 [[- 8]], or a salt[[,]] or solvate, ~~or a physiologically functional derivative~~ thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

Claims 10 - 12 (Cancelled)

13. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by ~~at least one of~~ inappropriate ALK5 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim[[s]] 1 [[- 8]], or a salt[[,]] or solvate, ~~or a physiologically functional derivative~~ thereof.

14. (Currently Amended) A method according to claim 13 wherein the disorder mediated by inappropriate ALK5 activity is chronic renal disease, acute renal disease, wound healing, photoaging of the skin, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any

disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, ~~for example,~~ hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol-induced hepatitis, haemochromatosis and primary biliary cirrhosis, and restenosis.

Claims 15 - 16 (Cancelled)